All Posts Tagged With: "BMRN"
(MYGN) Myriad Inks Deal with Cephalon
The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals...
(QGEN) Qiagen Expands with New Deals
In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight...
(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress
Recently, BioMarin Pharmaceutical Inc. (BMRN) commenced a mid-stage study of its pipeline candidate GALNS (N-acetylgalactosamine 6-sulfatase) in children suffering from mucopolysaccharidosis IVA (MPS IVA),...
(BMRN) BioMarin Pharmaceutical to Buy Pfizer Plant
BioMarin Pharmaceutical Inc. (BMRN) recently announced that it will acquire an integrated biologics manufacturing plant from pharma giant Pfizer Inc....
(BMRN) BioMarin Pharmaceutical – Bear of the Day
We are downgrading BioMarin Pharmaceutical Inc. (BMRN) to Underperform from Neutral following the below-par showing of the company in the final quarter of 2010. Earnings were hurt by lower-than-expected revenues....
(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing
Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on...
(MRK) Pharma Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert
Wednesday, July 28, 2010: Issue #1311
In...
(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up
by Marc Lichtenfeld, Healthcare Expert
Wednesday, July 28, 2010: Issue #1311
In...
(BMRN) BioMarin Pharma Announces Good News
BioMarin Pharma Inc. (BMRN) announced recently that its product Firdapse (Amifampridine phosphate) for treating Lambert Eaton Myasthenic Syndrome (LEMS) is commercially available in the European Union.
While...
(BMRN) BioMarin Pharmaceutical’s Earnings Top Analyst Estimates
BioMarin Pharmaceutical Inc. (BMRN) reported fourth-quarter 2009 earnings of 13 cents per share (excluding special items), beating the Zacks Consensus Estimate of break-even earnings. The company had earned...
(BMRN) BioMarin Pharmaceutical Announces Plan to Expand
BioMarin Pharmaceutical Inc. (BMRN) announced recently that it will purchase the privately-held drug discovery and early stage development company LEAD Therapeutics. LEAD is developing LT-673, an orally available...
(BMRN) BioMarin Pharma’s Drug Cleared in Europe
BioMarin Pharma Inc. (BMRN) announced recently that its drug candidate 3, 4-diaminopyridine amifampridine phosphate (3,4-DAP), indicated for treating Lambert Eaton Myasthenic Syndrome (LEMS), has received...
(BMRN) BioMarin Pharmaceutical Earns Orphan Status From FDA
Recently, BioMarin Pharmaceutical Inc. (BMRN) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug status to its candidate 3,4-diaminopyridine amifampridine phosphate (3,4-DAP),...
(ASH) Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks
by Marc Lichtenfeld, Healthcare Expert
Wednesday, November 11, 2009: Issue...
(BMRN) BioMarin Pharmaceutical Purchases Huxley Pharmaceuticals
Recently, BioMarin Pharmaceutical Inc. (BMRN) announced that it has acquired the privately held Huxley Pharmaceuticals Inc., which possessed rights to a proprietary form of 3,4-diaminopyridine amifampridine...
(BMRN) BioMarin Pharmaceutical Begins Mid-Stage Trial
Yesterday, BioMarin Pharmaceutical Inc. (BMRN) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria (PKU). The company expects initial results from the study in mid-2010. It is co-developing the candidate with Merck Serono...